← Back to Clinical Trials
Recruiting NCT07646418

NCT07646418 Combined Effects of LIRT-BFR Therapy in Post- Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07646418
Status Recruiting
Phase
Sponsor Riphah International University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 64 participants
Start Date 2025-06-01
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Low intensity resistance training with Blood flow restriction therapyConventional Physical Therapy Protocol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 64 participants in total. It began in 2025-06-01 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Stroke is a focal neurological deficit of sudden onset, with symptoms lasting more than 24 hours leading to consequences like impacting physical abilities, cognitive functions and emotional well-being, speech and language difficulties. Among various rehabilitation program, Blood flow restriction (BFR) therapy with low intensity resistance training has shown its promising results. Blood flow restriction training, also called Kaatsu, originated in Japan. So this study aims to determine the combined effects of Low Intensity Resistance Training with Blood Flow Restriction Therapy on Upper Limb Strength, Forward Reach and Sensorimotor function in Post-Stroke Patients.

Eligibility Criteria

Inclusion Criteria: * • 50 to 70 year of age (5) * Both males and females (5) * Generalized stroke population (both ischemic and hemorrhagic stroke) (9). * Post stroke patient after 1 month (5) * Barthel index scores ≥ 20 (10) * Spasticity level according to Modified Ashworth scale should be 1/+1 grade in the affected upper limb(7) * Muscle strength at grade 3 according to MMT of affected upper limb (7) Exclusion Criteria: * • People with a history of mental/cognitive illness (9) * History of transient ischemic attack (TIA) or recurrent stroke (8) * Diabetes with peripheral neuropathy (5) * Having resting blood pressure above 160/100 mmHg even after taking medications * Cardiovascular comorbidity (heart failure, unstable angina, aortic stenosis)

Contact & Investigator

Central Contact

Imran Amjad, PhD

✉ imran.amjad@riphah.edu.pk

📞 03324390125

Principal Investigator

Aiza Yousaf, MS-OMPT

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07646418 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 70 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07646418 currently recruiting?

Yes, NCT07646418 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT07646418 trial being conducted?

This trial is being conducted at Sialkot, Pakistan.

Who is sponsoring the NCT07646418 clinical trial?

NCT07646418 is sponsored by Riphah International University. The principal investigator is Aiza Yousaf, MS-OMPT at Riphah International University. The trial plans to enroll 64 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology